Abstract
Introduction
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a coinhibitory molecule expressed on activated T cells and regulatory T cells. CTLA-4 is essential in maintaining immune homeostasis and contributes to immune tolerance by downregulating T-cell activation (1) (2) (3) . Ipilimumab is a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that blocks CTLA-4. Two pivotal phase III trials in patients with advanced melanoma showed a survival benefit for ipilimumab as monotherapy or when added to chemotherapy (4, 5) , leading to its approval by the U.S. Food and Drug Administration in March 2011, marking a milestone in the field of immunotherapy. Immunotherapeutic strategies have also focused on targeting antigens expressed exclusively on melanoma cells, for example, melanoma differentiation antigens (such as gp100 or Melan-A) or cancer/testis (CT) antigens. CT antigens are expressed in a variety of human malignancies but not in normal adult tissues except for the testis and placenta (6) . To date, the best characterized CT antigen is NY-ESO-1, which is highly immunogenic and elicits spontaneous antibody and T-cell responses in patients with cancer whose tumors express NY-ESO-1 (7) . Prior studies by our group and others have shown that ipilimumab treatment of patients with advanced melanoma induces polyfunctional NY-ESO-1-and Melan-A-specific CD8 þ T-cell responses (8, 9) . We have also correlated the induction of polyfunctional NY-ESO-1 CD4 þ T-cell responses with the development of integrated antibodies and CD8 þ T-cell responses in patients, who experience clinical benefit (10) . The essential role of CD4 þ T helper (T H ) cells in enhancing and sustaining CD8 þ T-cell responses is well established (11) .
direct roles for tumor-reactive CD4 þ T cells for cancer immunotherapy (12, 13) . Specifically, CTLA-4 blockade has the capacity to expand antigen-specific cytotoxic CD4 þ T cells in vivo in mice (12) . Furthermore, adoptive transfer of CD4 þ T cells expanded from a single tumor-reactive T-cell clone resulted in a durable complete response in a patient with melanoma (14) . However, the cytotoxic function of antigenspecific CD4 þ T cells during ipilimumab treatment and its intracellular mechanism have not been characterized. We hypothesized that CTLA-4 blockade could result in expansion and/or enhancement of cytotoxic CD4 þ T-cell responses in human cancer patients through the modulation of T H 1 transcription factors. To address this question, we conducted indepth immune monitoring of 4 NY-ESO-1 seropositive melanoma patients who were treated with ipilimumab and had availability of properly annotated specimens. Peripheral blood mononuclear cells (PBMC) were analyzed by intracellular cytokine staining (ICS) using multiparametric flow cytometry. Samples were analyzed following in vitro stimulation with NY-ESO-1 overlapping or single peptides. IFN-g ELISPOT was conducted to define specific CD4 þ T-cell peptide responses.
Transcription factors T-bet and Eomesodermin (Eomes) as well as cytotoxic degranulation markers perforin and granzyme B were analyzed on NY-ESO-1-specific CD4 þ T cells.
NY-ESO-1-specific CD4
þ T-cell lines were established to confirm their ability to recognize NY-ESO-1-positive tumor cell lines and to induce tumor lysis.
Materials and Methods

Patients
Blood and tissue samples were analyzed from 4 patients (09-079-1, 09-079-7, 09-079-10, and 09-079-17) treated on a clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) evaluating the pharmacokinetics of two different biosynthetic formulations of ipilimumab (CA184-087, NCT00920907). All patients received 4 doses of antibody at a dose of 10 mg/kg i.v. administered every 3 weeks for 4 doses during induction therapy. Patients without dose-limiting toxicity and with evidence of clinical benefit (in this case, 09-079-1, 09-079-10, and 09-079-17) then received maintenance ipilimumab at the same dose every 12 weeks starting at week 24. Responses were adjudicated by the recently proposed immune-related response criteria (15) . Toxicity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. All patients provided informed consent for the clinical studies and additional consent for the collection of blood and tumor tissue for investigational purposes on a separate MSKCC biospecimen utilization protocol. All studies were approved by the MSKCC Institutional Review Board.
Peptides and cell lines
NY-ESO-1 overlapping peptides (17 peptides with $20-mer length and 10 aa overlap) (16) and NY-ESO-1 92-100 peptide (LAMPFATPM), NY-ESO-1 94-102 peptide (MPFATP-MEA), NY-ESO-1 94-104 peptide (MPFATPMEAEL), NY-ESO-1 96-104 peptide (FATPMEAEL), and NY-ESO-1 157-165 peptide (SLLMWITQC) were purchased from JPT Peptide Technologies. Peptides were dissolved in dimethyl sulfoxide at a concentration of 1 mg/mL and stored in aliquots at À80 C before use. The following autologous or MHC-matched melanoma cell lines were used as target cells: SK-MEL-381 (from patient 09-079-7) and SK-MEL-351 (from patient 09-079-10, NY-ESO-1 negative). Autologous B-lymphoblastoid cell lines (LCL) were generated in our laboratory from the patients' PBMCs, using EBV-containing supernatants and also used as target cells.
gen presenting cells or T-APCs) were prepared as described previously (17) (18) (19) . CD4 þ T cells were separated from PBMCs using Dynabeads (Invitrogen) according to the manufacturer's instruction and seeded into 48-well plates (NUNC) at a density of 1-2 Â 10 6 cells per well in 1 mL RPMI-1640 medium supplemented with 25 mmol/L HEPES, 10% heat-inactivated human AB serum (Gemini Bio-Products), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (complete medium). A total of 10 mg/mL of PHA (REMEL) was added to the culture at day 0. Half of the medium was replaced with complete medium containing interleukin (IL)-2 (20 IU/mL, Roche) and IL-7 (40 ng/mL; R&D systems) at day 3, which was then repeated twice weekly. The activated CD4 þ T-APCs were pulsed with peptides and used as target cells in various assays.
In vitro sensitization for monitoring T-cell immune responses
In vitro sensitization was conducted as described previously (17) (18) (19) (20) Generation of NY-ESO-1-specific CD4 þ T-cell lines NY-ESO-1-specific CD4 þ T cells were isolated by CD154 (CD40L) expression sorting as described with some modification (21, 22) . Presensitized CD4 þ T cells were restimulated for 6 hours in 500 mL X-VIVO15 (BioWhittaker-Lonza) with T-APCs that were pulsed overnight with NY-ESO-1 peptide (1 mmol/L) and labeled with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen-Molecular Probes) in the presence of 20 mL of phycoerythrin (PE)-conjugated anti-CD154 mAb and 0.3 mL GolgiStop (BD Biosciences). CFSE
effector T cells were sorted using a FACSAria instrument and FACS Diva software (BD Biosciences). Sorted cells were stimulated with plate-bound anti-CD3 (0.5 mg/mL) and CD28 mAbs (0.5 mg/mL; eBioscience) in the presence of irradiated allogeneic PBMCs and were expanded for about 20 days in the presence of 20 IU/mL of IL-2 and 20 ng/ml of IL-7 in complete medium as described with some modification (23) . Reactivity of the CD4 þ T-cell lines was tested against autologous melanoma cell lines or autologous LCL pulsed with peptides.
ELISPOT assay
The IFN-g ELISPOT assay was conducted as described previously (18) (19) (20) . Briefly, 96-well nitrocellulose ELISPOT plates (MAHA S4510; Millipore) were coated overnight at 4 C with 2 mg/mL anti-human IFN-g mAb (1-D1K) and blocked with 10% human AB serum-containing RPMI-1640 for 2 hours at 37 C. A total of 2 Â 10 4 sensitized CD4 þ T cells and 2 Â 10 4 peptide-pulsed T-APCs were placed in each well of the ELI-SPOT plate at a final volume of 200 mL RPMI-1640 medium without serum. After incubation for 22 hours at 37 C in a CO 2 incubator, the plate was developed using 0.2 mg/mL biotinylated anti-human IFN-g mAb (7-B6-1, Mabtech), 1 mg/mL streptavidin-alkaline phosphatase conjugate (Roche Diagnostics), and 5-bromo-4-chloro-3-indolyl phosphate/NBT (SigmaAldrich). The number of spots was evaluated using a C.T.L. Immunospot analyzer and software (Cellular Technology). Results were shown as the number of spot-forming cells (SFC) without subtracting the number of background spots, as the number of SFC in negative control was less than 3 spots per well in all assays. A positive response with more than 10 spot counts per well as well as spot counts !3-fold more than background spots obtained with nonpulsed target cells was considered to be significant.
Intracellular cytokine staining
For surface staining, APC-Cy7-CD8, PE-Cy7-CD3, Pacific Blue-CD3 (BD Bioscience), ECD-CD4, ECD-CD45RA, ECD-CD45RO (Beckman Coulter Inc.), and FITC-CCR7 (R&D Systems) were used. For ICS, in vitro stimulated and cultured were <0.1%, except for the transcription factors T-bet and Eomes, which were <0.5%.
Cytotoxicity assay
A cytotoxicity assay was conducted as described previously with some modifications (12) . To determine the in vitro killing of tumor targets, target cells were labeled with 0.5 mmol/L CFSE, whereas control target cells were labeled with 5 mmol/L CFSE. NY-ESO-1-specific CD4 þ T cell lines were cocultured at different ratios (24) 
Statistical analysis
Data were analyzed using Prism 5.0 (GraphPad Software, Inc.). All the experiments were repeated two or three times. Statistical significance was determined by a Student t test. P < 0.05 was considered a statistically significant difference.
Results
Patients
Patient profiles and clinical demographics are summarized in Table 1 .
Case 1-Patient 09-079-1
Patient 09-079-1 is a 63-year-old man with metastatic melanoma to soft tissue, liver, lymph nodes, bone, and left adrenal gland. He had experienced progressive disease (PD) on multiple chemotherapy regimens. In August 2009, he initiated ipilimumab therapy. After completing induction therapy, imaging at week 12 revealed PD but repeat imaging at week 24 showed a partial response (PR), although the adrenal lesion was noted to have increased in size. He initiated maintenance ipilimumab and subsequently underwent resection of the adrenal metastasis during week 27, as a presumed immunologic "escape" lesion. Since that time, he has maintained a durable PR.
Case 2-Patient 09-079-7
Patient 09-079-7 is a 49-year-old man who was diagnosed with metastatic melanoma to the lung, lymph nodes, pancreas, retroperitoneum, bone, soft tissue, thoracic nodes, and spleen in April 2009. He received first-line therapy with ipilimumab. Imaging after induction therapy revealed PD. Further imaging at week 16 indicated further significant PD. He was taken off the study protocol, transitioned to supportive care, and died in March 2010.
Case 3-Patient 09-079-10
Patient 09-079-10 is a 39-year-old woman with stage IV melanoma to the lung, liver, lymph nodes, spleen, and bone, with prior PD on a cisplatin/vinblastine/temozolomide. She initiated ipilimumab therapy in September 2009. Imaging after completing induction therapy revealed PD at week 12 but stable disease (SD) at week 24. She then received maintenance ipilimumab, with her last treatment in July 2011. She continues to have SD.
Case 4-Patient 09-079-17
Patient 09-079-17 is a 54-year-old woman with recurrent melanoma to the back, abdomen, and pelvis. This patient has a history of melanoma dating back to 1990, when she had a 2.4-mm melanoma with deep dermal invasion removed from her left lower back. She was disease free for approximately 15 years. She was noted to have a recurrence in 2005 and underwent multiple resections, including dermal, axillary node, and mesenteric masses. She previously experienced progression of disease on temozolomide, a gp100 DNA vaccine, talimogene laherparepvec (recombinant attenuated herpes simplex virus expressing GM-CSF) and high-dose IL-2. She then initiated protocol therapy with ipilimumab in October 2009. Computed tomographic imaging revealed PD at week 12 and SD at week 24. She received maintenance ipilimumab, and approximately 2.5 years into this treatment, she continues to have SD.
Ipilimumab therapy induces T H 1-dominant CD4
þ T-cell responses against multiple NY-ESO-1-specific epitopes in all four patients Sera collected from these 4 patients were analyzed for NY-ESO-1 antibody responses. All four patients were seropositive at baseline (Patients 09-079-7, -10 and -17) or following ipilimumab treatment (Patient 09-079-1). NY-ESO-1 antibody titers increased in all 4 patients, especially in patient 09-079-1, with subsequent ipilimumab treatments (Supplementary Table S1) as we have reported previously (10) . We confirmed baseline NY-ESO-1 antigen expression in tumor tissue from all 4 patients by immunohistochemistry and reverse-transcriptase PCR.
Purified CD4 þ T cells isolated from PBMCs were stimulated in vitro with NY-ESO-1 overlapping peptides and cultured for 20 days. Reactivity against NY-ESO-1 overlapping peptides and the individual NY-ESO-1 peptides was then determined for these cultured CD4 þ T cells by ICS and IFN-g ELISPOT assay. In CD107a with/without IL-2) were detected in all 4 patients. These cells did not secrete T H 2 cytokines (IL-4, IL-5, or IL-13) or T H 17 cytokine (IL-17A) by ICS, suggesting that that they are T H 1 cells. (Fig. 1A ) Because of the low frequency of NY-ESO-1 antigen-specific CD4 þ T cells in peripheral blood in these 4 patients, we did not detect NY-ESO-1 antigen-specific CD4 þ T-cell response using ex vivo ICS staining. After 20 days of in vitro cell culture, we were able to obtain approximately 5 Â 10 6 CD4 þ T cells with an 
Prior therapy
Temozolomide None CVT Gp100 DNA, High-dose IL-2, Oncovex IMC-1121BþDTIC CVT Total # of doses High-avidity CD4 þ T-cell responses with cytotoxicity to naturally processed antigen are detected in peripheral blood after ipilimumab treatment We sought to determine whether the NY-ESO-1-specific CD4 þ T cells detected after ipilimumab treatment had highaffinity T-cell receptors capable of recognizing naturally processed tumor antigen. NY-ESO-1 single peptide-specific CD4 þ T-cell lines were generated from PBMCs from patients 09-079-1 and -17 before and after the treatment at weeks 7 and 24 or from patients 09-079-7 and -10 at weeks 12 and 24 by a CD154 (CD40L) sorting method ( Supplementary Fig. S1A ) after stimulation with individual, dominant NY-ESO-1 peptides. We confirmed that there were no contaminating CD8 þ T cells in antigen-specific cytokine secretion and CD107a mobilization of CD4 þ T cells were assessed against NY-ESO-1 overlapping peptides by ICS assay.
Autologous T-APCs were used as target cells for ICS assay. Representative data from two or three independent experiments for each patient are shown. B, the specificity of CD4 þ T cells was tested using autologous T-APCs pulsed with each individual peptide or overlapping peptides by IFN-g ELISPOT assay.
Experiments were repeated twice to confirm the peptide reactivity. Ã , Peptide mix; all of NY-ESO-1 overlapping peptides mixture, with number of spots indicated.
autologous melanoma cell lines and autologous APC (EBVinfected B cell lines; LCLs) with each corresponding peptide or MAGE-A4 overlapping peptides as the negative control. The NY-ESO-1-specific CD4 þ T-cell lines established from 4
patients' expressed intracellular IFN-g, granzyme B, and surface CD107a, as compared with the CD4 þ T-cell response to the negative control ( Fig. 2A and B) . All NY-ESO-1-specific CD4 þ T-cell lines before and after the treatment were of high avidity to recognize 10 to 100 nmol/L peptide (data not shown). Furthermore, they recognized recombinant NY-ESO-1 protein naturally processed in autologous APCs (LCLs) by ELISPOT assay (Fig. 2C ) and lysed autologous LCL pulsed with corresponding NY-ESO-1 protein (100 nmol/L; Fig. 2D ) using the cytotoxicity assay described above. NY-ESO-1-specific CD4 þ T-cell lines lysed the autologous LCL pulsed with each cognate peptides (100 nmol/L) at 5:1 and 25:1 effector:target ratio (Fig. 2E) . Among the autologous melanoma cell lines derived from these patients, SK-MEL-381 (from patient 09-079-7) expresses both NY-ESO-1 and MHC class II. The NY-ESO-1 81-100 -specific CD4 þ T-cell line from patient 09-079-7 lysed the autologous tumor cell line (SK-MEL-381), and cytotoxicity was inhibited by MHC class II antibody blocking of the target cells (Fig. 2F) . The NY-ESO-1-specific CD4 þ T-cell lines do not coexpress CD8 markers before and after restimulation in the ICS assay (Supplementary Fig. S1C ).
Serial changes in cytotoxic NY-ESO-1 antigen-specific CD4 þ T cells after ipilimumab treatment
From patient 09-079-17, we were able to establish NY-ESO-1 131-150 peptide-specific CD4 þ T-cell lines at the pretreatment time point as well as at weeks 7 and 24 by the CD154 (CD40L) sorting method and subsequently analyzed serial changes in cytotoxic function. These cell lines recognized autologous APCs (LCLs) pulsed with NY-ESO-1 131-150 peptide (100 nmol/L) in the ICS assay. In contrast with IFN-g, which was consistently produced before and after the therapy, accumulation of granzyme B and perforin was observed only after ipilimumab treatment (Fig. 3A-C) . In addition, in vitro peptide restimulation induced granzyme B synthesis only in CD4 þ T cells after the therapy (Fig. 3C ). In accordance with the expression of cytotoxic molecules, higher expression of the transcription factor Eomes previously reported as the master regulator of cytotoxic CD8 þ T cell (30) was observed after ipilimumab treatment at weeks 7 and 24 when compared with expression levels before treatment ( Fig. 3D ; Ã , P < 0.05). In contrast, expression of T-bet was not increased (Fig. 3D) . Expression of PD-1 became lower at week 24 after treatment when compared with pretreatment and at week 7 ( Fig. 3D ; Ã , P < 0.05). We next assessed whether the ipilimumab-related changes in expression of lytic markers described above in the NY-ESO-1 131-150 -specific CD4 þ T-cell lines from patient 09-079-17
affected their ability to lyse autologous LCL pulsed with NY-ESO-1 131-150 peptides (100 nmol/L) at 5:1 and 25:1 E/T ratio. The degree of cytotoxicity (%) was significantly increased after ipilimumab treatment (peak at week 7), when compared with that of cells obtained pretreatment ( Ã , P < 0.05). This cytotoxicity was inhibited with the use of an MHC class II blocking antibody on target cells (Fig. 4) .
Discussion
In this study, we conducted in-depth immune monitoring on four NY-ESO-1-seropositive melanoma patients treated with ipilimumab, based upon the availability of suitable PBMCs. We found that NY-ESO-1 antigen-specific T H 1 responses against multiple epitopes were induced or expanded after ipilimumab treatment in all 4 patients. NY-ESO-1 antigen-specific CD4 þ Tcell lines established from all 4 patients were of high avidity and recognized naturally processed NY-ESO-1 protein in APCs, as indicated by the production of perforin, granzyme B, and the upregulation of CD107a. Finally, we showed that one of these NY-ESO-1 antigen-specific CD4 þ T-cell lines directly lysed autologous melanoma cells in an MHC class II-restricted manner. We believe this is the first demonstration of the induction or enhancement of tumor-reactive cytotoxic CD4 þ T cells after ipilimumab treatment and is therefore a novel property of CTLA-4 blockade. (32) . Our analysis showed that most of the NY-ESO-1-specific CD4 þ T-cell lines generated after ipilimumab treatment were of high avidity and recognized naturally processed NY-ESO-1 protein in APCs in specimens of the 4 patients analyzed, distinguishing these results from those of exogenous vaccination strategies. Our observation in this study was based upon the results collected from either in vitro culture of CD4 þ T cells or CD40L
sorted NY-ESO-1-specific CD4 þ T-cell lines. Because of the limited PBMC availability and low frequency of NY-ESO-1 antigen-specific CD4 þ T cells in peripheral blood from these patients, we were not able to characterize directly these NY-ESO-1 antigen-specific CD4 þ T cells in ex vivo assays.
The optimal T-cell receptor (TCR) affinity threshold for natural tumor recognition and maximal antitumor T-cell response has been measured using human CD8 þ T cells transduced with TCR variants (33) . Thus, the relative lack of high affinity/avidity TCRs for CD8 þ T cells is considered to be one reason why immune responses toward self-tumor antigens have not been protective. It is possible that the cytotoxic capacity of CD4 þ T cells might be subject to an optimal TCR affinity threshold as well. In this study, NY-ESO-1-specific CD4 þ T-cell lines were directly sorted from bulk CD4 þ T-cell cultures after one round of in vitro presensitization. Therefore, these CD4 þ T-cell lines, not "clones," reflect a spectrum of the 
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